invivoscribe

DECLARATION OF CONFORMITY

Manufacturer:

Invivoscribe, Inc.
10222 Barnes Canyon Rd. Bldg 1
San Diego, California 92121
United States of America

Authorized Representative:

Invivoscribe Technologies, SARL
c/o Ficorec Domicilation Services
132, Boulevard Michelet
Hall Nord - 5ème étage
13008 Marseille, FRANCE

UK Responsible Person:

Gillian Pawlowsky Ltd.
272 Bath Street
Glasgow G2 4JR
Scotland UK

Family Name:

LeukoStrat®

Device Trade Name:

***FLT3* Mutation Assay**

Catalog #	Device	Quantity	Basic UDI-DI	GTIN	EMDN Code
K4120291	LeukoStrat® CDx FLT3 Mutation Assay	33 Tests	081002273K41202914S	00850052003715	W01060299

I, the undersigned, hereby declare that the *in-vitro* diagnostic medical devices specified above conform to the European Directive 98/79/EC, *In vitro* Diagnostic Medical Device Directive, Annex III.

I, the undersigned, hereby declare that the *in-vitro* diagnostic medical devices specified above conform to the Part IV of the UK Medical Device Regulations 2002, Annex III (as modified by Part III of the Schedule 2A to the UK MDR 2002).

*Date of Validity: 10 Oct 2023

By: Jason Gerhold

Jason Gerhold
Global Director of Quality, Regulatory and Clinical Affairs
Invivoscribe, Inc.
10222 Barnes Canyon Rd. Bldg 1
San Diego, California 92121
USA

*Originally signed on 05/18/2022, no significant changes have occurred to the product since that date